Compare PODD & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PODD | VTRS |
|---|---|---|
| Founded | 2000 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 17.2B |
| IPO Year | 2007 | 2019 |
| Metric | PODD | VTRS |
|---|---|---|
| Price | $215.93 | $13.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 4 |
| Target Price | ★ $357.65 | $13.50 |
| AVG Volume (30 Days) | 839.7K | ★ 9.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.59% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.48 | N/A |
| Revenue | $2,708,100,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $24.33 | $4.45 |
| Revenue Next Year | $19.33 | $1.79 |
| P/E Ratio | $64.99 | ★ N/A |
| Revenue Growth | ★ 30.73 | N/A |
| 52 Week Low | $216.49 | $6.85 |
| 52 Week High | $354.88 | $16.47 |
| Indicator | PODD | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 40.04 |
| Support Level | N/A | $12.92 |
| Resistance Level | $299.75 | $16.38 |
| Average True Range (ATR) | 7.61 | 0.40 |
| MACD | -0.52 | -0.11 |
| Stochastic Oscillator | 1.66 | 30.38 |
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.